These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 14089298)

  • 1. STUDIES ON THE SITE OF ACTION OF A CIRCULATING ANTICOAGULANT IN DISSEMINATED LUPUS ERYTHEMATOSUS. EVIDENCE THAT THIS ANTICOAGULANT INHIBITS THE REACTION BETWEEN ACTIVATED STUART FACTOR (FACTOR X) AND PROACCELERIN (FACTOR V).
    BRECKENRIDGE RT; RATNOFF OD
    Am J Med; 1963 Dec; 35():813-9. PubMed ID: 14089298
    [No Abstract]   [Full Text] [Related]  

  • 2. Circulating anticoagulant in disseminated lupus erythematosus. Proposed mode of action.
    Veltkamp JJ; Kerkhoven P; Loeliger EA
    Haemostasis; 1973-1974; 2(6):253-9. PubMed ID: 4137579
    [No Abstract]   [Full Text] [Related]  

  • 3. THE MODE OF ACTION OF A COAGULATION INHIBITOR IN THE BLOOD OF TWO PATIENTS WITH DISSEMINATED LUPUS ERYTHEMATOSUS (DLE).
    BIGGS R; DENSON KW
    Br J Haematol; 1964 Apr; 10():198-216. PubMed ID: 14141619
    [No Abstract]   [Full Text] [Related]  

  • 4. Studies on a circulating anticoagulant in systemic lupus erythematosus: evidence for inhibition of the function of activated plasma thromboplastin antecedent (factor XIa).
    Krieger H; Leddy JP; Breckenridge RT
    Blood; 1975 Aug; 46(2):189-97. PubMed ID: 237589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anticoagulants with antithrombinase activity in systemic lupus erythematosus (author's transl)].
    Jungers P; Dougados M; Ganzegel C; Kremp O; Jacques C; Noel LH; Josso F
    Nephrologie; 1980; 1(2):67-8. PubMed ID: 7301023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The activated seven lupus anticoagulant assay detects clinically significant antibodies.
    Moore GW; Rangarajan S; Savidge GF
    Clin Appl Thromb Hemost; 2008 Jul; 14(3):332-7. PubMed ID: 17895508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lupus anticoagulant screening: comparison of 5 tests (author's transl)].
    Follea G; Ffrench P; Trzeciak MC; Dechavanne M
    Nouv Rev Fr Hematol (1978); 1981; 23(4):203-7. PubMed ID: 7312614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRYOCOAGULOPATHY WITH PRESENCE OF IMMUNOANTITHROMBIN IN THE COURSE OF LUPUS ERYTHEMATOSUS DISSEMINATUS.
    STRUZIK T; HANICKI Z; HAWIGER J; BIERNACKA B
    Acta Med Pol; 1964; 5():61-80. PubMed ID: 14133809
    [No Abstract]   [Full Text] [Related]  

  • 9. A clinical study of the lupus anticoagulant.
    Schleider MA; Nachman RL; Jaffe EA; Coleman M
    Blood; 1976 Oct; 48(4):499-509. PubMed ID: 963290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor V anticoagulants: clinical, biochemical, and immunological observations.
    Feinstein DI; Rapaport SI; McGehee WG; Patch MJ
    J Clin Invest; 1970 Aug; 49(8):1578-88. PubMed ID: 4194089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on phospholipids in the action of a lupus coagulation inhibitor.
    Exner T; Rickard KA; Kronenberg H
    Pathology; 1975 Oct; 7(4):319-28. PubMed ID: 1223721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NATURALLY OCCURRING SPECIES SPECIFIC INHIBITOR OF HUMAN PROTHROMBIN IN LUPUS ERYTHEMATOSUS.
    HOUGIE C
    Proc Soc Exp Biol Med; 1964 Jun; 116():359-61. PubMed ID: 14189138
    [No Abstract]   [Full Text] [Related]  

  • 13. Purification and kinetic studies on a circulating anticoagulant in a suspected case of lupus erythematosus.
    Yin ET; Gaston LW
    Thromb Diath Haemorrh; 1965 Sep; 14(1-2):88-115. PubMed ID: 16955969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on a circulating anticoagulant in procainamide-induced lupus erythematosus.
    Edwards RL; Rick ME; Wakem CJ
    Arch Intern Med; 1981 Nov; 141(12):1688-90. PubMed ID: 6171218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of action of the lupus anticoagulant.
    Shapiro SS; Thiagarajan P; De Marco L
    Ann N Y Acad Sci; 1981; 370():359-65. PubMed ID: 6791549
    [No Abstract]   [Full Text] [Related]  

  • 16. [Leiden, G20210A mutations in prothrombin gene and antiphospholipid antibodies in systemic lupus erythematosus and antiphospholipid syndrome].
    Reshetniak TM; Patrushev LI; Stukacheva EA; Miroshnikov AI; Tikhonova TL; Nasonov EL; Alekberova ZS
    Ter Arkh; 2000; 72(5):34-8. PubMed ID: 11109617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unusual circulating anticoagulant in a patient with systemic lupus erythematosus.
    SANCHEZ-MEDAL L; LISKER R; TORRE LOPEZ E
    Acta Haematol; 1963 Feb; 29():117-22. PubMed ID: 13991388
    [No Abstract]   [Full Text] [Related]  

  • 18. [On the presence of circulating anticoagulants in a case of systemic lupus erythematosus. Preliminary studies].
    Porro T; Sideri GC; Valentini R
    Haematol Lat; 1968; 11(1):31-7. PubMed ID: 5722007
    [No Abstract]   [Full Text] [Related]  

  • 19. [FUNCTIONAL RELATION BETWEEN ERYTHROPLASTIN (ERYTHROCYTE COAGULANT FACTOR) AND PLASMA FACTORS: PROACCELERIN (V), PROCONVERTIN (VII) AND STUART FACTOR(X)].
    GAERTNER H; CAEN J
    Acta Physiol Pol; 1964; 15():237-43. PubMed ID: 14227143
    [No Abstract]   [Full Text] [Related]  

  • 20. Oral anticoagulation reduces activated protein C less than protein C and other vitamin K-dependent clotting factors.
    Simmelink MJ; de Groot PG; Derksen RH; Fernandez JA; Griffin JH
    Blood; 2002 Dec; 100(12):4232-3. PubMed ID: 12393585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.